1
Nucleome has appointed Dr Michelle Morrow as CSO
Nucleome Therapeutics, a company tackling the molecular causes of inflammatory diseases through a breakthrough approach to 3D human genetics, has announced the appointment of Dr Michelle Morrow as Chief Scientific Officer (CSO).
Michelle joins Nucleome with two decades of experience in drug discovery and development and executing R&D strategy across biotech and large pharma.
Most recently she was CSO at Avacta Therapeutics, where she provided strategic leadership of discovery and preclinical research and led its oncology programme through…